

Revision date: 02-Jan-2007 Version: 2.6 Page 1 of 6

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Atarax® (Hydroxyzine hydrochloride) tablets

Trade Name: Atarax (R)
Chemical Family: Mixture

Intended Use: Pharmaceutical product used for sedative, anxiolytic, Antipruritic.

2. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS List	%
Alginic acid	9005-32-7	232-680-1	*
Hydroxyzine hydrochloride	2192-20-3	218-586-3	12.5 - 32.6
Starch	9005-25-8	232-679-6	*
Magnesium stearate	557-04-0	209-150-3	*

Ingredient	CAS Number	EU EINECS List	%
Calcium phosphate dibasic, anhydrous	7757-93-9	231-826-1	*
Lactose	63-42-3	200-559-2	*
Polyethylene alycol	25322-68-3	Not listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

3. HAZARDS IDENTIFICATION

Appearance: Tablets, varying in color depending on strength

Signal Word: WARNING

Statement of Hazard: May be harmful if swallowed.

Possible risk of harm to the unborn child. May cause central nervous system effects.

Additional Hazard Information:

Short Term: Accidental ingestion may cause effects similar to those seen in clinical use. **Long Term:** Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: The most commonly reported adverse effects seen with the use of hydroxyzine include

drowsiness, somnolence, headache, weakness, depression, and irritability.

EU Indication of danger: Harmful

Toxic to Reproduction; Category 3

Material Name: Atarax® (Hydroxyzine hydrochloride) tablets

Revision date: 02-Jan-2007 Version: 2.6

EU Hazard Symbols:



EU Risk Phrases:

R22 - Harmful if swallowed.

R63 - Possible risk of harm to the unborn child.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Page 2 of 6

Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. Get medical attention.

Skin Contact: Remove clothing and wash affected skin with soap and water. If irritation occurs or persists,

get medical attention. This material may not be completely removed by conventional

laundering. Consult professional laundry service. Do not home launder.

Ingestion: Get medical attention immediately. Do not induce vomiting unless directed by medical

personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention

immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride

and other chlorine-containing compounds.

Fire Fighting Procedures: Wear approved positive pressure, self-contained breathing apparatus and full protective turn

out gear.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

Page 3 of 6

Material Name: Atarax® (Hydroxyzine hydrochloride) tablets

Revision date: 02-Jan-2007 Version: 2.6

7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with

eyes.

Storage Conditions: Keep container tightly closed when not in use. Store out of direct sunlight in a well ventilated

area at room temperature.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Hydroxyzine hydrochloride

Pfizer OEL TWA-8 Hr: 0.3 mg/m³

Starch

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total

= $5 \text{ mg/m}^3 \text{ TWA}$ = $10 \text{ mg/m}^3 \text{ TWA}$

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA **Australia TWA** = 10 mg/m³ TWA

Magnesium stearate

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA except stearates of toxic metals

Australia TWA = 10 mg/m³ TWA

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with

large quantities.

Eyes: Not required under normal conditions of use. Glasses or goggles are recommended if eye

contact is possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with

large quantities.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit

(OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control

exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Tablet Color: Red, yellow, orange, green

Odor: Odorless Molecular Formula: Mixture

Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability:StableConditions to Avoid:None knownIncompatible Materials:Strong oxidizers

Hazardous Decomposition Products: No data available

Page 4 of 6

Material Name: Atarax® (Hydroxyzine hydrochloride) tablets

Revision date: 02-Jan-2007 Version: 2.6

Polymerization: Will not occur

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Alginic acid

Rat Oral LD50 > 5 g/kg

Lactose

Rat Oral LD50 > 10 g/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m³

Starch

Mouse IP LD50 6600 mg/kg

Hydroxyzine hydrochloride

Rat Oral LD50 840 mg/kg
Mouse IP LD50 81 mg/kg
Rat IP LD50 160 mg/kg
Mouse IV LD50 137 mg/kg
Rat IV LD50 45 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

<u>Irritation / Sensitization: (Study Type, Species, Severity)</u>

Polyethylene glycol

Eye Irritation Rabbit Mild Skin Irritation Rabbit Mild

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

No data available

Hydroxyzine hydrochloride

Reproductive & Fertility Rat Oral 400 mg/kg LOAEL Developmental toxicity, Reproductive toxicity

Reproductive Effects

Mutagenicity

Teratogenicity Hydroxyzine when administered to the pregnant mouse, rat, and rabbit, induced fetal

abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Hydroxyzine has been associated with teratogenesis in beagle puppies. In pregnant monkeys (one per dose group), oral doses of 6, 8, and 12 mg/kg resulted in abortion in all three

pregnancies. However, dosing at 5 or 10 mg/kg did not produce abortions, nor were any gross malformations seen in offspring.

No data available

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

At increase risk from exposure: Individuals with a history of hypersensitivity to this material or other materials in its chemical

class may be susceptible to the toxicity of overexposure. Individuals taking central nervous system depressants (alcohol, hypnotics, narcotics, barbiturates) should avoid exposure to this

material.

Page 5 of 6

Material Name: Atarax® (Hydroxyzine hydrochloride) tablets

Revision date: 02-Jan-2007 Version: 2.6

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to

the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Harmful

Toxic to Reproduction; Category 3

EU Risk Phrases:

R22 - Harmful if swallowed.

R63 - Possible risk of harm to the unborn child.

EU Safety Phrases:

S22 - Do not breathe dust.

S36 - Wear suitable protective clothing.

S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:

WARNING

May be harmful if swallowed.

Possible risk of harm to the unborn child. May cause central nervous system effects.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Alginic acid

Page 6 of 6

Material Name: Atarax® (Hydroxyzine hydrochloride) tablets

Revision date: 02-Jan-2007 Version: 2.6

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-680-1

Hydroxyzine hydrochloride

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS List

218-586-3

Calcium phosphate dibasic, anhydrous

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
231-826-1

Starch

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-679-6

Lactose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
200-559-2

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
209-150-3

Polyethylene glycol

Inventory - United States TSCA - Sect. 8(b) XU
Australia (AICS): Present

16. OTHER INFORMATION

Reasons for Revision: Updated Section 3 - Hazard Identification. Updated Section 5 - Fire Fighting Measures.

Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 15 -

Regulatory Information.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet